As shown in the experimental timeline (Fig. 1B), which is similar to the strategy we previously employed to genetically target Kat5 (Wang et al., 2022), we assessed the effect of daily intraperitoneal administration of 10 mg/kg TH1834, beginning on day 3 after MI or sham surgery, for 14 consecutive days, ending on day 16 post-MI. The gene discussed is KAT5; the disease is myocardial infarction.